Navigating Cannabis Regulation in Washington, D.C.: A Complex Market Shaped by Federal Oversight

By Charles Alovisetti, David M. Ullian, Jack Crain

Dec 9, 2025

Washington, D.C.’s cannabis market operates under one of the most complex regulatory structures in the United States. Shaped by limited home rule, congressional oversight, and a series of evolving local reforms, D.C.’s cannabis framework reflects the tension between local autonomy and federal authority. This article outlines how the District’s political foundation, legal milestones, and current regulations continue to define its cannabis industry.

An Overview of Washington, D.C.’s Evolving Cannabis Framework

Washington, D.C., was established as a neutral federal district in 1790 when Congress, under Article I, Section 8 of the Constitution, created a capital distinct from any state.¹ The land was ceded by Maryland and Virginia to form a ten-mile-square district along the Potomac River, though Virginia’s portion was later returned in 1846.² For much of its history, Congress governed the District directly, leaving residents without voting representation and limited local authority. Pressure for reform, fueled by debates over taxation without representation and civil rights, culminated in the 20th century with demands for home rule.

The District of Columbia Home Rule Act of 1973 marked a turning point. It created an elected mayor and 13-member Council, transferring many powers of governance from Congress to local officials. However, Congress retained the ability to review and overturn local legislation and to control the District’s budget through appropriations.³ The Act also established Advisory Neighborhood Commissions (ANCs) - grassroots, nonpartisan bodies that give residents a voice in local governance. ANCs provide recommendations on zoning, licensing, and transportation that agencies must give “great weight.”⁴ This hybrid model allows D.C. to function as both a city and a quasi-state while remaining constitutionally subordinate to Congress (a dynamic that continues to shape every major policy issue, including cannabis).

A Brief History of Cannabis Reform in the District

Washington, D.C. voters first approved reform in 1998 with Initiative 59, authorizing medical cannabis recommendations for serious illnesses. Congress immediately blocked implementation through the Barr Amendment, which prohibited use of funds to enact the law.⁵ Only after the rider’s repeal in 2009 did the District proceed to establish a regulated medical program.⁶

In 2010, the Legalization of Marijuana for Medical Treatment Amendment Act created a framework for licensed cultivation and dispensaries under the D.C. Department of Health.⁷ The first medical cannabis dispensaries opened in 2013.⁸ This program laid the foundation for today’s Medical Cannabis Program, now administered by the D.C. Alcoholic Beverage and Cannabis Administration (ABCA).⁹

D.C. voters advanced further reform with Initiative 71 (2014), legalizing possession of up to two ounces, home cultivation, and non-remunerative transfers (also referred to as “gifting”) of cannabis between adults 21 years of age and older for personal use. Congress responded with the Harris Rider (2015), which barred D.C. from using local funds to regulate or tax adult-use cannabis sales—effectively freezing implementation of a retail market. In response, a gray market emerged as “I-71 stores” began selling non-cannabis items such as t-shirts and pencils accompanied by “gifted” cannabis and operating without oversight.¹⁰

Recognizing the persistence of unregulated cannabis sales and growing patient demand, the Medical Cannabis Amendment Act of 2022 (MCAA) overhauled the Medical Cannabis Program. It expanded patient access through self-certification, created new medical cannabis business license categories (including courier, manufacturer, and internet retailer), and prioritized social equity applicants. Oversight transferred to the ABCA and the Alcoholic Beverage and Cannabis Board (ABC Board), aligning cannabis regulation with D.C.’s existing regulatory framework for alcohol.¹¹

Subsequent statutory measures, such as the Unlicensed Establishment Enforcement Clarification Emergency Amendment Act of 2025, strengthened enforcement against unlicensed retail stores distributing cannabis while preserving D.C.’s limited home-rule authority.¹²

Current Cannabis Laws and Regulatory Framework

Several key statutes, regulations, and executive orders govern the D.C. cannabis regulatory framework, including:

Ongoing rulemaking and advisory opinions, available on the ABCA website, address operational standards, licensing updates, and enforcement priorities.¹³ Additional laws, such as Chapter 16C (Penalties for commercial property owners of illegal cannabis businesses) and the Medical Cannabis Program Enforcement Emergency Amendment Act of 2024, target illegal enterprises and clarify regulatory jurisdiction.¹⁴

Hemp Regulation in D.C.

Unlike federal law and the law in most states in the U.S., D.C. law does not distinguish hemp from marijuana. Under D.C. Code § 7-1671.01 et seq. and 22-C DCMR § 100 et seq., all cannabinoid-containing products—including products containing cannabinoids derived from hemp—are classified as “cannabis.”¹⁵ A 2021 D.C. Attorney General memorandum confirmed that “CBD is cannabis,” citing the absence of a hemp carve-out.¹⁶ Consequently, all cannabinoid products must be sold through licensed medical dispensaries to registered patients.

This approach has led to litigation, including Capitol Hemp, LLC v. United States of America, challenging the District’s treatment of hemp and the congressional ban on non-medical sales.¹⁷ However, given prevailing trends in state-level regulation, such challenges face an uphill battle. More recent decisions concerning challenges to D.C.’s cannabis laws reflect this uphill battle, including DeLorean 88 LLC v. District of Columbia, where the D.C. District Court refused to accept Plaintiff’s argument that the 2018 Farm Bill preempted D.C.’s laws prohibiting the sale of cannabis and cannabis products without a medical cannabis business license issued by ABCA.¹⁸

Regulatory Agencies and Oversight

The Alcoholic Beverage and Cannabis Board (ABC Board) is an independent entity composed of up to seven members, appointed by the Mayor and confirmed by the Council. It meets weekly to approve licenses, adjudicate violations, and adopt regulations.¹⁹ The Alcoholic Beverage and Cannabis Administration (ABCA) implements these policies, issues and renews licenses, conducts inspections, and manages patient registration and outreach.²⁰

Licensing and Social Equity Programs

D.C.’s medical cannabis program features seven (7) medical cannabis business license types: cultivation center, manufacturer, retailer, internet retailer, courier, testing laboratory, and certification training provider.²¹ Retailers may also hold endorsements for safe-use treatment facilities, education tasting, delivery, and summer gardens.²²

The most recent licensing round closed on August 29, 2024, with no new rounds expected soon.²³ Entry into the market currently requires acquisition of an existing license.

Under D.C. law, at least 50% of all new licenses issued must be reserved for social equity applicants,²⁴ defined as entities with majority ownership by D.C. residents meeting at least two of the following criteria:

Returning citizens (formerly arrested, convicted, or incarcerated for a cannabis or drug-related offense);
Close family member of individuals arrested, convicted, or incarcerated for a cannabis or drug-related offense; or
Household income at or below 150% of the U.S. HUD median family income.²⁵

Conditional licensees initially had one year to commence operations, though this period has been extended to up to three years as many conditional licensees struggle to secure property and financing.²⁶

Deal Structuring Issues

Ownership and Control Limits

Under D.C. Code § 7-1671.06, multiple license rights for certain types of medical cannabis businesses are restricted. For example, a licensee cannot hold more than a total of three retailer and internet retailer licenses, and a cultivator licensee cannot hold more than one retailer license.²⁷ Conflict of interest provisions also limit ownership interest and control rights in a variety of ways to prevent market consolidation.²⁸ Straw ownership of social equity applicants is expressly prohibited.²⁹

All ownership and control interests must be disclosed to the ABCA, and a change in majority ownership or controlling interest requires prior ABC Board approval.³⁰ A license is considered a revocable privilege, not a property right, and cannot be sold, assigned, transferred, pledged, or otherwise encumbered without prior approval.

Equity Financings

A change in equity holders owning 1% or more of the licensee requires disclosure of all required information regarding the new equity holder to the ABCA within 15 calendar days.³¹ This is in contrast to states like Colorado and Ohio, where no immediate disclosure is required for changes involving non-material (i.e. less than 10%) equity holders.³²

Mergers & Acquisitions

All cannabis-related M&A transactions require Board approval before any change of ownership or control takes effect.³³

Debt Financings

Pre-approval is required if a loan grants control, equity rights, or is secured by the license. Routine financing (such as term loans or lines of credit without conversion rights) typically requires only disclosure, not prior Board approval.³⁴ The terms of debt should be carefully reviewed to determine the appropriate regulatory approach (i.e., if it requires pre-approval).

Market Trends

D.C.’s regulated medical cannabis market continues to improve despite previously exhibiting early signs of saturation. According to ABCA’s October 2025 report, total sales increased from $7.82 million in September to $8.96 million in October, a substantial improvement following two consecutive months of declining total sales. The patient base, which dropped from 19,052 in August to 18,497 in September, rebounded to 20,649. The average transaction value remained at $63 for October after falling from $65 in August to $63 in September.³⁵

Data from prior recent months shows steady patient demand but flattening revenue as more dispensaries compete for the same consumers. Now, with these recently reported October improvements, operators within D.C.’s regulated market have good cause to remain optimistic. Nonetheless, competition, especially amongst retailers, remains strong despite these reported improvements in consumer demand, and market participants must endure through financial constraints within the District’s evolving cannabis market.

Wholesale price compression continues as more cultivators commence operations and cut margins to maintain shelf space. Retailers rely on discounts and restricted advertising to attract and retain patients, even as compliance costs rise. Meanwhile, enforcement against unlicensed operators, including I-71 gifting stores, has intensified; more than 84 unlicensed stores, including retailers selling hemp-derived THC products, have been shut down since enforcement efforts ramped up in July 2024.³⁶ Legal operators have yet to see price recovery, suggesting a maturing market characterized by thin margins, increased competition, and a shift toward efficiency and vertical integration.

If you’re navigating medical cannabis, hemp-derived products, licensing, or enforcement issues in Washington, D.C., Vicente LLP’s cannabis and regulatory team is here to help. Contact us to discuss your business goals and compliance strategy.

¹ The History of Washington, DC, Washington.org, https://washington.org/DC-information/washington-dc-history (last visited Nov. 6, 2025).
² Washington, D.C., History Resources, Geo. Univ. Libr., https://guides.library.georgetown.edu (May 28, 2025).
³ D.C. Home Rule, Council of the Dist. of Columbia, https://dccouncil.gov/dc-home-rule/ (last visited Nov. 6, 2025).
⁴ D.C. Code § 1-309.10(d)(3)(A) (2025).
⁵ Federal Court Allows DC Government to Tally Medical Marijuana Initiative Vote, Am. Civ. Liberties Union (Sept. 17, 1999), https://www.aclu.org/press-releases/federal-court-allows-dc-government-tally-medical-marijuana-initiative-vote.
⁶ Federal Policy, Marijuana Policy Project, https://www.mpp.org/policy/federal/ (Oct. 9, 2025).
⁷ Legalization of Marijuana for Medical Treatment Amendment Act of 2010, D.C. Law 18-210 (Aug. 6, 2010).
⁸ First 3 Washington DC Marijuana Dispensaries Open, But Initial Market Size is Miniscule, MJBizDaily, https://mjbizdaily.com/first-3-washington-dc-medical-marijuana-dispensaries-open-but-initial-market-size-miniscule/ (Dec. 17, 2021).
⁹ Alcoholic Beverage & Cannabis Admin., https://abca.dc.gov/ (last visited Nov. 6, 2025).
¹⁰ Summary of D.C.’s Initiative 71, Marijuana Policy Project, https://www.mpp.org/states/district-of-columbia/summary-of-d-c-s-initiative-71/ (last visited Nov. 6, 2025).
¹¹ Medical Cannabis Amendment Act of 2022, D.C. Law 24-332 (Mar. 22, 2023).
¹² Unlicensed Establishment Enforcement Clarification Emergency Amendment Act of 2025, D.C. Act 26-38 (Mar. 21, 2025).
¹³ Alcoholic Beverage & Cannabis Admin., supra note 9.
¹⁴ D.C. Code § 7-1675.01 (2025); Medical Cannabis Program Enforcement Emergency Amendment Act of 2024, D.C. Act 25-371 (Jan. 25, 2024).
¹⁵ D.C. Code §§ 7-1671.01(2A), 48-901.02(3) (2025); 22-C DCMR § 9900.1 (2025).
¹⁶ Memorandum from Brian K. Flowers, Deputy Att’y Gen., Legal Couns. Div., to Jonathan Berman, Assistant Gen. Couns., Alcoholic Beverage Regul. Admin. 2 (Apr. 28, 2021).
¹⁷ Capitol Hemp, LLC v. U.S., No. 1:25-cv-01797 (D.D.C. dismissed Nov. 24, 2025).
¹⁸ DeLorean 88 LLC v. District of Columbia, No. 1:25-cv-02458 (D.D.C. Oct. 8, 2025).
¹⁹ ABC Board, Alcoholic Beverage & Cannabis Admin., https://abca.dc.gov/page/abc-board (last visited Nov. 6, 2025).
²⁰ Alcoholic Beverage & Cannabis Admin., supra note 9.
²¹ Medical Cannabis Business Licenses, Alcoholic Beverage & Cannabis Admin., https://abca.dc.gov/page/medical-cannabis-business-licenses (last visited Nov. 6, 2025).
²² D.C. Code §§ 7-1671.06c – 7-1671.06f (2025).
²³ Medical Cannabis – Open Application Schedule, Alcoholic Beverage & Cannabis Admin., https://abca.dc.gov/page/medical-cannabis-open-application-schedule (last visited Nov. 6, 2025).
²⁴ D.C. Code § 7-1671.06(h) (2025).
²⁵ D.C. Code § 7-1671.01(20C).
²⁶ 70 D.C. Reg. 1582, 1599 (Feb. 3, 2023).
²⁷ D.C. Code § 7-1671.06(e) (2025).
²⁸ D.C. Code § 7-1671.06(e) (2025); 22-C DCMR §§ 5413, 5501.5, 6401.1, 6401.2 (2025).
²⁹ D.C. Code § 7-1671.06(j) (2025).
³⁰ D.C. Code § 7-1671.06(r)(1) (2025); 22-C DCMR §§ 5501, 5502 (2025).
³¹ 22-C DCMR § 5501 (2025).
³² Colo. Rev. Stat. §§ 44-10-309, 44-10-312(4) (2025); Ohio Admin. Code 1301:18-1-01(A)(30), 1301:18-3-04(A)(1) (2025).
³³ 22-C DCMR §§ 5501, 5502 (2025).
³⁴ 22-C DCMR §§ 5404.3, 5501, 5502 (2025).
³⁵ Medical Cannabis Program Report | October 2025, Alcoholic Beverage & Cannabis Admin., https://abca.dc.gov/sites/default/files/dc/sites/abra/page_content/attachments/MCP%20Report%20-%20October%202025%20%281%29.pdf (last visited Dec. 5, 2025).
³⁶ ABCA and MPD Shut Down Illegal Cannabis Operations at Puff Puff Pass, Smoke Shop, Inc., and YouGroGurl, DC.gov (Nov. 10, 2025, 3:00 PM), https://content.govdelivery.com/accounts/DCWASH/bulletins/3fa7994.